MAINTAIN-POPNCT06925061
Target Engagement of EXL01 in the Prevention of Post-operative Recurrence of Crohn's Disease
At risk: Primary completion moved at least 3 months later.
Track this trial
Free. We email you which fields changed when ClinicalTrials.gov updates this record.
Record History
All 4 versions: 4 with changes below. See every version on ClinicalTrials.gov ↗
- Notable Eligibility criteria expanded, about 20 words
- Primary completion pushed from Sep 13, 2026 to Dec 31, 2026
- Interventions: After surgery for Crohn's disease, eligible patients will be randomized 1:1 to receive oral EXL01 or placebo with or without SoC treatment… to After surgery for Crohn's disease, eligible patients will be randomized 1:1 to receive oral EXL01 or placebo with or without SoC treatment…
- Minor Study description expanded, about 214 words
- Site details revised at 9 of 12 sites
- Minor Start date: Mar 13, 2025 to Mar 31, 2025v2
- Study First Submitted
- Notable: the plan changed
- Minor: routine updates
Endpoints
Primary
To compare the distribution of endoscopic modified Rutgeerts scores, as centrally assessed, at 6 months post-surgery in patients with CD treated with EXL01 to patients treated with placebo.
Timeframe: From enrollment to the end of treatment at 24 weeks
Arms and interventions
Live biotherapeutic product (EXL01)Experimental
EXL01 administered with or without SoC treatment orally, once a day during 24 weeks
PlaceboPlacebo comparator
Placebo administered with or without SoC treatment orally, once a day during 24 weeks
Drugs: After surgery for Crohn's disease, eligible patients will be randomized 1:1 to receive oral EXL01 or placebo with or without SoC treatment (based on investigator decision) for up to 24 weeks
Sites
12 sites in 1 country